Beaumont Patients 1st to get Next Generation of Radiation... ( ROYAL OAK Mich. Sept. 20 /- Cance...)

Beaumont Patients 1st to get Next Generation of Radiation Treatment

Date:9/20/2007

ROYAL OAK, Mich., Sept. 20 /PRNewswire/ -- Cancer patients at Beaumont Hospitals are the first in the world to be treated with the next generation of radiation therapy that is painless, faster, more accurate and precise than other treatments.

Beaumont doctors and physicists invented and patented the new technology, Omnibeam(R). The $3.3-million machine is manufactured in England by Elekta, which is headquartered in Stockholm. The first patient was treated on Sept. 10.

The painless treatment takes about 20 minutes and requires no implants or invasive procedures to prepare for therapy. It can be used to treat cancer of the breast; prostate; lungs; and head and neck, as well as other cancers. It is specially designed for the treatment of tumors deep within the body.

Omnibeam(R), a robotic technology, uses highly accurate, real-time CT imaging that automatically adjusts the radiation field during treatment to account for a patient's external movements - and the natural repositioning of internal organs - from day to day or even moment to moment. Omnibeam(R) also uses robotic technology to adjust the treatment table on which a patient lies to provide pinpoint accuracy of treatment. Adjusting the radiation field and treatment table means the radiation treatment is precisely targeted to kill cancer cells, destroying them without harming surrounding healthy tissue or organs. The patient has better cancer control and fewer undesirable side effects as a result.

"Omnibeam(R) is a dramatic new clinical advance in radiation therapy for cancer. The combination of improved imaging coupled with robotic technology is vastly better than other radiation machines for cancer therapy," says Alvaro Martinez, M.D., corporate chairman of Radiation Oncology for Beaumont Hospitals. "It uses advanced imaging technology, is faster, can treat from very small to very large, irregularly shaped tumors and does not require placement of metal implants as with other thera
'/>"/>

1

GOOD

Page: 1 2
Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients

Post Your Comments:

Beaumont Patients 1st to get Next Generation of Radiation...( ROYAL OAK Mich. Sept. 20 /- Cance...),Health